NOXXON To Present Latest Clinical Data from Nox-A12 / Keytruda® Combination Trial at Esmo Immuno-Oncology Congress on Decemb...

Poster Title: Safety and clinical outcome in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoi...

Oncosec Medical (ONCS) Announces Updated Tumor Responses in KEYNOTE-695 Study of TAVO Plus KEYTRUDA in Refractory Metastatic Melanoma

Eligible patients in KEYNOTE-695 had refractory, locally advanced or metastatic disease defined as unresectable Stage III/IV metastatic melanoma that had definitively progressed on a full-course of an...